Delivery Order SPE2DB20D2104-SPE2DB25FMZDR
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) on August 8, 2025, with a ceiling value of $3,831.81 and an ultimate completion date of August 11, 2025. This non-set-aside, competitively awarded delivery order utilizes firm fixed pricing and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $12,290.03 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count supply) on July 23, 2025, with completion scheduled for July 24, 2025. This non-competitive delivery order utilizes firm fixed pricing and is performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, fulfills this...
- The Defense Logistics Agency awarded a delivery order valued at $4,232.99 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (30-count) on July 29, 2025, with an ultimate completion date of July 30, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's Corporate Office located in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order valued at $7,437.20 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) on August 28, 2025, with completion targeted for August 29, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's Corporate Office, with performance occurring at the company's headquarters in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) at a ceiling value of $2,378.33. This competitively awarded, firm fixed-price delivery order is scheduled for ultimate completion on August 29, 2025, with performance to be executed at AmerisourceBergen's Conshohocken, Pennsylvania location. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $88,661.75 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count units) on August 4, 2025, with an ultimate completion date of August 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor...
- The Defense Logistics Agency awarded a $2,801.52 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Gemtesa 75 mg tablets (90-count units). This is a non-set-aside competitive award with an ultimate completion date of August 21, 2025 and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $3,661.12 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count units) on August 20, 2025, with an ultimate completion date of August 21, 2025. This firm fixed-price delivery order represents a non-competitive set-aside contract and is being performed at the vendor's Conshohocken, Pennsylvania location. As a child order under a larger contract vehicle, this delivery supports the federal government's pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $7,747.10 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90 count) on August 12, 2025, with completion scheduled for August 13, 2025. This competitively awarded, firm fixed price contract represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) with a ceiling value of $1,722.87. This firm fixed-price delivery order, awarded on July 30, 2025, with an ultimate completion date of July 31, 2025, represents a non-competitive award under an existing contract vehicle. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, which serves as AmerisourceBergen's corporate headquarters and...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMZDRDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $7,959.64 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count supply) on August 29, 2025, with an ultimate completion date of September 2, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement, fulfills this order under its larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery order represents one of numerous pharmaceutical supply transactions through AmerisourceBergen's comprehensive IDC vehicle, which supports military healthcare systems and other federal agencies including the Defense Health Agency and U.S. Coast Guard. The underlying IDC serves as a global pharmaceutical support mechanism enabling the contractor to supply a wide range of medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to military installations and veteran healthcare networks worldwide. This particular transaction for Gemtesa, a medication used in urology, exemplifies the contractor's role in supporting diverse medical supply requirements across the Defense Department's healthcare enterprise.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.0k | 8/29/25 |